Ultimovacs ASA
ULTI.OL
Get informed when a big investor buys or sells
+ FollowMarket Cap$577.98M
Close$
Share Statistics
| Market cap | $577.98 Million |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.5 |
| Beta | 0.79 |
| Outstanding Shares | 7,749,100 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -3.99 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Zelluna ASA
15 employees
CEO: Namir Hassan Established in 2016 and headquartered in Oslo, Norway, Zelluna ASA specializes in the creation of T-cell receptor (TCR) cellular immunotherapy treatments aimed at combating solid tumors.